Jeanmarie Guenot is Guiding Amphivena Therapeutics in the Fight Against Life-threatening Diseases

 

JeanMarie Guenot got a Ph.D. from the University of California and an advanced degree in business administration from the University of Pennsylvania. Guenot has two decades of work experience in the biotechnology and pharmaceutical industry. She has managed high-profile research institutions and pharmaceutical firms.

 

Guenot’s work experience

 

Guenot began her career in 1993 at Hoffman-La Roche as a scientist. She participated in the development of drugs for various medical conditions such as autoimmune diseases, inflammation, melanomas, and metabolic diseases. In 2000, Guenot joined Atlas Venture as an associate. Her role in this company was to manage capital investments. Three years later, she was appointed VP of PDL BioPharma. Guenot spearheaded activities in the corporate and business development division of the company.

Her role was to oversee mergers & acquisitions, licensing, management of product portfolios, and alliances. In 2008, she launched Guenot, LLC and served as its managing partner. A year later, she co-founded SKS Ocular, LLC. This company pioneered the development of unrelenting release ocular drug conveyance technologies, dry AMD, Ocular inflammation, and therapeutics for glaucoma.

 

Jeanmarie Guenot and Amphivena Therapeutics enters an agreement with Janssen Biotech

 

Amphivena Therapeutics is a biotechnology company established in 2012. This California-headquartered company specializes in the development of immunotherapy technologies for hematologic malignancies. A year after its inception, Amphivena Therapeutics raised about $14 million in its first series of financing with the help of MPM Capital. In 2013, this company made a deal with Janssen Biotech, which gave Janssen the power to acquire Amphivena with the approval of IND.

 

In 2015, Amphivena announced its achievement under its new agreement with Janssen. This company selected a candidate to participate in clinical trials for a new tumor antigen. This success prompted the issuance of funds to Amphivena by Johnson & Johnson Innovation. Amphivena’s candidate was given RECRUIT-TandAb, a drug conjugate with bi-specific molecules that bind on tumor cells and cause cell lysis. RECRUIT-TandAb is showing promising results in the fight against cancer.

According to JeanMarie Guenot, this discovery is a significant milestone for the company and the science fraternity. She also added that Amphivena Therapeutics would continue to conduct more research to address the various forms of life-threatening cancers.  BusinessWire writes more about what Jeanmarie has done, and continues to do in the future through biotechnology.

Leave a Reply

Your email address will not be published. Required fields are marked *